Successful Response of Pembrolizumab Rechallenge after Radiotherapy for a Patient with Bladder Cancer of Nonresponse of Pembrolizumab First Challenge

We report a patient with advanced bladder cancer in which the primary lesion and metastatic site disappeared following the pembrolizumab therapy rechallenge after radiotherapy for bladder cancer lesion of nonresponse of pembrolizumab first challenge. A 76-year-old man with advanced bladder cancer re...

Full description

Saved in:
Bibliographic Details
Published inCase reports in urology Vol. 2021; pp. 1 - 5
Main Authors Ikeda, Taro, Hasegawa, Go, Kawaguchi, Gen, Ikeda, Yohei, Hara, Noboru, Nishiyama, Tsutomu
Format Journal Article
LanguageEnglish
Published New York Hindawi 28.07.2021
Hindawi Limited
Wiley
Subjects
Bladder cancer
Cancer therapies
Case Report
Case reports
Chemotherapy
Hydronephrosis
Immunotherapy
Lymphatic system
Metastasis
Monoclonal antibodies
Patients
Radiation therapy
Targeted cancer therapy
Tumors
Urology
Online AccessGet full text

Cover

More Information
Summary:We report a patient with advanced bladder cancer in which the primary lesion and metastatic site disappeared following the pembrolizumab therapy rechallenge after radiotherapy for bladder cancer lesion of nonresponse of pembrolizumab first challenge. A 76-year-old man with advanced bladder cancer received three courses of the chemotherapy with gemcitabine and cisplatin combination; however, the chemotherapy was stopped because of adverse events. The patient started pembrolizumab therapy; however, the effect was not observed. Radiation therapy was given to the primary lesion and pelvic lymph node metastases for the purpose of local control of the lesions. Because the primary lesion was regrowth and para-aortic lymph node metastasis appeared, pembrolizumab therapy was resumed. Thereafter, the primary lesion and metastatic site disappeared.
Bibliography:Academic Editor: Fumitaka Koga
ISSN:2090-696X
2090-6978
DOI:10.1155/2021/9087529